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All known recently emerged human coronaviruses probably originated in bats1. Here 
we used a single experimental platform based on human lung-only mice (LoM) to 
demonstrate efficient in vivo replication of all recently emerged human coronaviruses 
(SARS-CoV, MERS-CoV and SARS-CoV-2) and two highly relevant endogenous 
pre-pandemic SARS-like bat coronaviruses. Virus replication in this model occurs in 
bona fide human lung tissue and does not require any type of adaptation of the virus 
or the host. Our results indicate that bats harbour endogenous coronaviruses capable 
of direct transmission into humans. Further detailed analysis of pandemic 
SARS-CoV-2 in vivo infection of LoM human lung tissue showed predominant 
infection of human lung epithelial cells, including type II pneumocytes present in 
alveoli and ciliated airway cells. Acute SARS-CoV-2 infection was highly cytopathic and 
induced a robust and sustained type I interferon and inflammatory cytokine/
chemokine response. Finally, we evaluated a therapeutic and pre-exposure 
prophylaxis strategy for coronavirus infection. Our results show that therapeutic and 
prophylactic administration of EIDD-2801, an oral broad spectrum antiviral currently 
in phase II–III clinical trials, dramatically inhibited SARS-CoV-2 replication in vivo and 
thus has significant potential for the prevention and treatment of COVID-19.
The recently emerged human pandemic coronavirus Severe Acute Res-
piratory Syndrome coronavirus-2 (SARS-CoV-2), the causative agent of 
coronavirus disease (COVID)-19, has resulted in substantial morbidity 
and mortality worldwide2. Bats are the presumed source of SARS-CoV-2 
and the highly pathogenic human coronaviruses SARS-CoV and Middle 
East Respiratory Syndrome (MERS)-CoV1. Transmission of coronavi-
ruses from bats to other species is well-documented and adaptation 
in an intermediary host can facilitate their transmission to humans1. 
While it is possible that SARS-CoV-2 was transmitted to humans via an 
intermediate host, phylogenic analysis indicates that the SARS-CoV-2 
lineage has circulated in bats for decades and evolved in bats into a virus 
capable of replicating in human cells3. Given the repeated and accel-
erating emergence of highly pathogenic coronaviruses, it is increas-
ingly important to monitor and characterize bat coronaviruses and to 
identify the viral determinants of human infection, disease, and global 
spread as well as to develop effective therapeutic interventions. Animal 
models are useful in studying highly pathogenic human coronaviruses, 
the emergence potential of zoonotic coronaviruses, and to evaluate the 
in vivo inhibitory activity of novel agents4–15. However, human coronavi-
ruses do not replicate in mice without either extensive virus adaptation, 
genetic editing of the host receptor, or introduction of the appropriate 
human receptor genes into the host4,6–13,15. Although existing rodent 
models of coronavirus infection have made several important contri-
butions, none possesses the diverse set of primary human lung cells 
that serve as targets for viral infection16. Here, we show that human 
lung-only mice (LoM), immune deficient mice implanted with authentic 
human lung tissue17, allow for the in vivo study of SARS-CoV, MERS-CoV, 
and SARS-CoV-2 in a single platform permitting direct comparison of 
experimental outcomes. Using LoM, we also show efficient replication 
of bat coronaviruses in vivo without the need for virus adaptation. 
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In addition, we performed an in-depth in  vivo analysis of acute 
SARS-CoV-2 infection in the human lung which revealed robust virus 
replication, pathogenesis, and sustained activation of the innate host 
immune response. Finally, we used this platform to show that EIDD-
2801, an orally administered broad spectrum antiviral currently in 
phase II-III clinical trials for COVID-19 treatment, efficiently inhibited 
SARS-CoV-2 replication in human lung tissue when administered thera-
peutically and prevented SARS-CoV-2 infection when administered 
as pre-exposure prophylaxis strongly supporting its further clinical 
development for COVID-19.
Coronavirus replication in LoM
LoM are constructed by subcutaneous implantation of human lung tis-
sue into the back of immune deficient mice (Fig. 1a). This tissue expands 
to form a palpable implant17 (Fig. 1a). Lung implants contain human 
fibroblast, epithelial, endothelial, and mesenchymal cells that form 
cartilaginous and non-cartilaginous bronchial airways lined with cili-
ated and non-ciliated epithelium, alveolar sac structures, and extensive 
vasculature17(Extended Data Fig. 1a,b). The human lung tissue in LoM 
has been shown to support replication of a diverse set of emerging and 
clinically relevant human pathogens including MERS-CoV17.
We evaluated the potential of LoM to serve as a single platform to 
study all known recently emerged human coronaviruses and the poten-
tial of endogenous bat coronaviruses for human emergence. Human 
angiotensin converting enzyme-2 (ACE2), the receptor for SARS-CoV 
and SARS-CoV-218–21, is expressed on human epithelial cells (cytokera-
tin 19+) in the human lung tissues of LoM (Extended Data Fig. 1c,d). 
Expression of transmembrane protease serine 2 (TMPRSS2), which 
primes the spike protein of SARS-CoV and SARS-CoV-218, was also con-
firmed (Extended Data Fig. 1e). LoM were inoculated with SARS-CoV, 
MERS-CoV, or SARS-CoV-2 (Extended Data Table 1). SARS-CoV and 
SARS-CoV-2 infection resulted in mean virus titers of 1.76x108 and 
2.42x107 PFU/g respectively at 2 days post-infection (Fig. 1b). Viral 
nucleoprotein antigen was abundantly observed in the human lung 
tissues of SARS-CoV and SARS-CoV-2 infected LoM (Extended Data 
Fig. 2a). Consistent with our previous results17, MERS-CoV replicated 
to mean titers of 4.79x108 PFU/g in LoM human lung tissues at 2 days 
post-infection (Fig. 1b) and abundant viral antigen was observed 
(Extended Data Fig. 2a).
Pre-pandemic bat coronaviruses WIV1-CoV and SHC014-CoV have 
high sequence homology to SARS-CoV, use ACE2 to infect human 
cells, and grow modestly in primary human airway cultures on liquid 
interface12,13. WIV1-CoV and SHC014-CoV efficiently replicated in the 
human lung tissue of LoM (Extended Data Table 1) with mean titers of 
1.58x107 and 1.48x107 PFU/g, respectively at two days post-exposure 
(Fig. 1b) and viral antigen was readily detected in human lung tissues 
(Extended Data Fig. 2b). No viral antigen was detected in human lung 
tissues of naïve LoM (Extended Data Fig. 2c). Collectively, these results 
demonstrate that LoM serve as single platform where recently emerged 
human coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 replicate 
efficiently in human lung tissue. Importantly, the efficient replication 
of SARS-like bat coronaviruses WIV1-CoV and SHC014-CoV observed is 
in agreement with previous in vitro data12,13 suggesting that bats harbor 
coronaviruses capable of direct transmission to humans, bypassing the 
need for further adaptation in an intermediary host.
SARS-CoV-2 replication in LoM
Human lung tissues of LoM were inoculated with SARS-CoV-2 and 
titers of replication competent virus determined 2, 6, and 14 days 
post-exposure (Fig. 1c, Extended Data Table 2). High titers of replica-
tion competent virus were noted at all time points although they were 
highest 2 days post-infection (Fig. 1c). Infection was widely distributed 
throughout the tissue with large numbers of cells positive for viral RNA 
(Fig. 1d) and nucleoprotein (Fig. 1e). Co-staining for human cytokeratin 
19 demonstrated that SARS-CoV-2 predominantly infects human epi-
thelial cells in the lung (Fig. 1f, Extended Data Fig. 3a). Viral antigen was 
not detected in human CD34 expressing (endothelial) cells and in only a 
few human vimentin expressing (mesenchymal) cells (Fig. 1f, Extended 
Data Fig. 3a). We further identified the types of infected epithelial cells. 
Virus antigen was clearly identified in cells which expressed pro-SP-C 
(alveolar type II [AT2] pneumocytes) or acetylated alpha-tubulin IV 
(ciliated cells); virus antigen was not detected in HT1-56 (alveolar type I 
[AT1] pneumocytes) or CC10 positive cells (club cells) (Fig. 1g, Extended 
Data Fig. 3b). These results demonstrate that SARS-CoV-2 has limited 
tropism in the lung with AT2 pneumocytes and ciliated airway epithelial 
cells being the predominant cells infected.
SARS-CoV-2 pathogenesis in LoM
Histopathologic analysis revealed several features of early diffuse 
alveolar damage that have been described in lung tissues of COVID-
19 patients including the accumulation of proteinaceous exu-
date and fibrin in alveolar spaces, desquamation of pneumocytes, 
multi-nucleated cell formation, and the appearance of fibrin thrombi 
in small vessels (Fig. 2)22–24. Proteinaceous exudate, including large pro-
tein globules, was observed in alveolar spaces, which overlapped with 
areas of virus accumulation (Fig. 2a,b). As early as 2 days post-infection, 
desquamation of pneumocytes was noted; a large number of virally 
infected cells were fully detached or detaching from the alveolar base-
ment membrane (Fig. 2c,d). Infected multi-nucleated cells were also 
observed (Fig. 2c). While hyaline membranes were not noted, in contrast 
to naïve LoM (Fig. 2e), fibrin was detected in alveolar spaces (Fig. 2f). 
Importantly, we observed multiple occluded vessels containing fibrin 
thrombi as reported in COVID-19 patient lungs (Fig. 2g)22–24. Electron 
microscopy demonstrated the normal architecture and integrity of 
uninfected AT2 pneumocytes in human lung tissue obtained from LoM 
two days post-infection (Fig. 2h). In contrast, AT2 cells containing virus 
particles in the same sample had swollen mitochondria with loss of 
matrix and cristae as well as rough endoplasmic reticula (RER) with 
distended cisternae, protein accumulation, and virus particles (Fig. 2i). 
Degenerative SARS-CoV-2 infected AT2 cells detached from the alveolar 
basal membrane were observed in the alveolar luminal space (Fig. 2j). 
Higher magnification revealed subcellular accumulation of virus con-
taining vesicles indicative of virus replication and egress. Virions with 
electron dense nucleocapsids and distinctive crown-like spikes were 
observed (Fig. 2i,j). Consistent with previous reports23,25, virions pro-
duced by human lung cells were pleomorphic in size (69 to 112 nm) 
and shape. Despite the extensive damage observed in the lung tissue, 
the endothelium in the majority of blood vessels was intact with tight 
junctions, numerous pinocytotic vesicles, and normal mitochondria 
and endoplasmic reticulum (Fig. 2k,l). Virions were not detected within 
endothelial cells in agreement with our immunofluorescence analysis 
(Fig. 1f and Fig. 2k,l). However, pleomorphic virions were present in 
capillary lumen surrounded by fibrillar protein deposits and cell debris 
(Fig. 2k,l). Together, these results demonstrate that acute SARS-CoV-2 
infection of LoM closely resembles lung infection in humans and is 
highly cytopathic resulting in significant injury to the fragile alveolar 
lung structures.
We performed RNA-sequencing analysis of human lung tissues col-
lected from animals 2, 6 and 14 days post-infection. Abundant viral 
transcripts were detected, ranging from 0.55% to 3.6% of the total reads 
at 2 days post-infection (Extended Data Table 3). Viral transcripts were 
abundant but lower at 6 days and 14 days post-infection (Extended 
Data Table 3). Sequencing data identified canonical SARS-CoV-2 
transcripts26 and confirmed maintenance of the furin cleavage site in 
the spike protein. Analysis of human gene transcripts revealed 1,504 
differentially expressed cellular genes between naïve and infected 














Supplementary Tables 1 and 2). Of these genes, differential expression 
analysis suggested 1,043 were increased and 461 were decreased in 
expression in the infected human lung tissue relative to naïve controls 
(Supplementary Tables 1 and 2). Three patterns of note: the expres-
sion of most genes did not change with infection, many genes with 
increased expression in SARS-CoV-2 infected LoM were lowly or mod-
erately expressed in naïve LoM, and a handful of genes went from either 
undetectable expression in naïve LoM to moderate/high expression in 
infected LoM or from expression in naïve LoM to undetectable expres-
sion in infected LoM. As expected, ACE2 and TMPRSS2 were expressed 
across the lung tissues (Extended Data Table 4). Notably, numerous 
interferon-stimulated genes (ISGs) and inflammatory cytokine genes, 
including pro-inflammatory cytokines genes IL6, CXCL8 (IL-8), CXCL10 
(IP-10), TNF, and CCL5 (RANTES) were potently induced in infected 
lung tissue (Supplementary Tables 1 and 2). We also observed dramatic 
upregulation of IFNB1, IFNL1, IFNL2, and IFNL3 expression (>1,000 
fold for all) at 2 days post-exposure, suggesting that these cytokines 
play a key role in the antiviral response to SARS-CoV-2 (Supplemen-
tary Tables 1 and 2). Gene set enrichment analysis (GSEA) showed 
over 840 gene pathways significantly upregulated (p<0.05) including 
response to type 1 interferon (p=0.0011), response to virus (p=0.0010), 
innate immune response (p=0.0010), cytokine mediated signaling 
(p=0.0010), cytokine production (p=0.0010), response to stress 
(p=0.0010), inflammatory response, (p=0.0010), NIK NF-KB signal-
ing (p=0.0011), acute inflammatory response (p=0.0035), regulation of 
cell death (p=0.0030), and coagulation pathways (p=0.0453) (Fig. 3b). 
Complement activation, which contributes to SARS-CoV pathogenesis 
in mouse models14, was also increased (p=0.0470) (Fig. 3b). Importantly, 
analysis of host gene expression at later time points demonstrated a 
sustained upregulation of antiviral and inflammatory genes that in 
some instances (e.g. ISG15, IFITM1, TNF, CXCL9) persisted for up to 
14 days post-infection (last time analyzed) (Fig. 3c,d, Extended Data 
Table 5, Supplementary Tables 1 and 2). These results demonstrate that 
acute SARS-CoV-2 infection causes a potent and sustained upregula-
tion of innate immune responses in virus-infected human lung tissue.
EIDD-2801 treatment and prophylaxis
The ribonucleoside analog β-D-N4-hydroxycytidine (NHC) broadly 
inhibits coronavirus infection in vitro in human airway epithelial 
cell cultures15. Prophylactic and therapeutic administration of its 
oral pro-drug EIDD-2801 (also known as molnupiravir or MK-4482) 
reduced SARS-CoV and MERS-CoV replication and pathogenesis in 
mice15. 5’-triphosphate NHC acts as a competitive alternate substrate 
for the viral RNA-dependent RNA polymerase allowing it’s incorpora-
tion into viral RNA resulting in the accumulation of mutations within 
the viral RNA genome leading to error catastrophe15. As an orally bio-
available agent, EIDD-2801 could be much more readily administered 
to patients compared to remdesivir and other antivirals and biologics 
(e.g. convalescent plasma and monoclonal antibodies) which require 
administration by infusion in a clinical setting. We tested the ability of 
therapeutic EIDD-2801 to inhibit SARS-CoV-2 replication in vivo using 
a dose which is also similar to the human dose in clinical trials27. LoM 
were administered EIDD-2801 starting 24 h or 48 h post SARS-CoV-2 
exposure and every 12 h thereafter (Extended Data Fig. 4a, Extended 
Data Table 6). Our results show that EIDD-2801 had a remarkable 
effect on virus replication after only two days of treatment (Fig. 4a,b). 
EIDD-2801 dramatically reduced the number of infectious particles in 
human lung tissue by 4.4 logs (>25,000 fold decrease) when treatment 
was initiated 24 h post-exposure (p=0.0002) (Fig. 4a). When treat-
ment was started 48 h post-exposure, virus titers were significantly 
reduced by 96% (1.5 logs, p=0.0019) (Fig. 4b). Next, we tested the effi-
cacy of EIDD-2801 pre-exposure prophylaxis. LoM were administered 
EIDD-2801 starting 12 h prior to SARS-CoV-2 exposure and every 12 h 
thereafter (Extended Data Fig. 4b, Extended Data Table 6). EIDD-2801 
pre-exposure prophylaxis significantly reduced virus titers in the 
human lung tissues of LoM by over 100,000 fold in two independent 
experiments (p=0.0002 and p=0.0068, Fig. 4c–e). Furthermore, in 
contrast to EIDD-2801 treated mice, abundant cell debris and nucleo-
protein positive cells could be readily observed in the alveolar lumen of 
vehicle control treated mice consistent with the extensive pathogenic 
effects inflicted on the lung by SARS-CoV-2 (Fig. 4f, g). These results 
demonstrate that prophylactic administration EIDD-2801 is highly 
effective at preventing SARS-CoV-2 infection and pathogenesis in vivo.
Discussion
Our results demonstrate replication of all known recently emerged 
human coronaviruses in LoM. Importantly, in agreement with in vitro 
studies12,13, our results demonstrate relatively efficient replication 
of two pre-pandemic endogenous bat viruses in human lung tissue 
in vivo indicating that coronaviruses circulating in bats have pandemic 
potential without the need for further adaptation to humans. Acute 
SARS-CoV-2 infection of LoM resulted in significant lung injury and 
exhibited key features of the extensive lung pathology observed in 
severe COVID-19 patients22,24,28,29. In agreement with analyses of bron-
choalveolar fluid obtained from COVID-19 patients and post-mortem 
patient lung samples5,30, multiple ISGs were significantly increased in 
SARS-CoV-2 infected human lung tissue of LoM. We observed robust 
induction of IFNB1 expression during acute infection followed by 
a decline in expression. Interestingly, an analysis of post-mortem 
COVID-19 patient lungs5 did not reveal increased IFNB1 expression 
and it has been shown in vitro that its expression is blocked during 
SARS-CoV infection31,32. These results suggest that in human lung tis-
sue IFNB1 expression is induced during acute SARS-CoV-2 infection. 
While this study was not designed to evaluate the effect of type I IFN 
on SARS-CoV-2 replication in vivo, in vitro studies and in vivo mouse 
studies showed that type I IFN treatment restricts SARS-CoV-2 repli-
cation7,33. We also observed increased expression of several human 
cytokine genes in SARS-CoV-2 infected LoM, many of which were also 
increased in analyses of COVID-19 patient serum and post-mortem lung 
tissue further establishing the similarities between LoM and human 
SARS-CoV-2 infection5,34.
Currently, the FDA approved SARS-CoV-2 vaccines are highly effec-
tive at preventing disease. However, it may take considerable time to 
reach target vaccination levels needed for herd immunity, especially in 
resource limited settings, due to manufacturing capabilities, required 
vaccine shipping and storage conditions, and public acceptance. There-
fore, alternative treatments and preventive approaches are still urgently 
needed. Remdesivir, is limited to use in hospitalized patients and its 
effectiveness at reducing disease and mortality late in infection is 
not clear35,36. While a carefully controlled NIH sponsored clinical trial 
reported that remdesivir significantly shortened the time of recov-
ery35, the WHO SOLIDARITY trial revealed no significant reduction in 
the duration of hospitalization or mortality36. Early administration of 
monoclonal antibody therapies bamlanivimab and REGN-CoV2 signifi-
cantly reduced viral loads in COVID-19 patients with mild to moderate 
disease37,38. However, they must be administered by infusion in a clinical 
setting limiting their potential for widespread use. A highly efficacious 
antiviral that is administered orally has potential for more widespread 
use and for administration to patients with mild to moderate disease39. 
Here, we show that EIDD-2801 administered therapeutically for only two 
days significantly reduced infectious virus titers in vivo by over 4 logs. 
The sooner EIDD-2801 treatment was initiated after SARS-CoV-2 expo-
sure, the greater the reduction in virus replication. We also observed 
that prophylactic administration of EIDD-2801 efficiently prevents 
SARS-CoV-2 infection in vivo highlighting its potential utility as an 
effective prophylactic and therapeutic agent against SARS-CoV-2 and 
other past and future zoonotic coronaviruses. NHC belongs to a class of 














and function. However, NHC did not cause significant mitochondrial 
toxicity or impair mitochondrial function in vitro40. Furthermore, no 
significant increase in transition frequencies in nuclear or mitochon-
drial message was detected in the lung tissue of ferrets dosed with 
EIDD-2801 for seven days consistent with the observed good toler-
ability of the drug41. Phase II and Phase II-III clinical trials are ongoing to 
evaluate EIDD-2801 safety and its effect on viral shedding using doses 
up to 1,600 mg/day twice daily, a dose that is expected to provide 
similar intracellular 5’-triphosphate NHC levels as a 300-500 mg/kg 
dose in mice. As with any antiviral, its therapeutic/prophylactic use 
will be dictated by risk/benefit. Limitations of our study include the 
absence of human nasal airway structures in LoM which are thought 
to be early sites of SARS-CoV-2 replication in humans42. Since LoM do 
not have an autologous human adaptive immune system they reflect 
the direct effect of viruses on their targets and bystander cells as well 
as their innate immune response to infection. Collectively, our results 
demonstrate the utility of LoM as a single in vivo platform to evaluate 
and compare the replication and pathogenesis of past, present, and 
future pre-emergent, epidemic, and pandemic coronaviruses accel-
erating the development and testing of therapeutic and pre-exposure 
prophylaxis agents such as EIDD-2801.
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Fig. 1 | Robust replication of recently emerged human and bat 
coronaviruses in LoM demonstrate the potential of bat coronaviruses for 
direct transmission to humans and the predilection of SARS-CoV-2 for 
infection of human epithelial cells. a, LoM construction and image of a 
human lung implant. b, Viral titers in the human lung tissue of LoM injected 
with SARS-CoV (n=14, red), MERS-CoV (n=16, orange), SARS-CoV-2 (n=7, blue), 
WIV1-CoV (n=6, green), or SHC014 (n=6, purple) as determined by plaque assay 
(PFU, plaque forming units). c, SARS-CoV-2 titers in the human lung tissue of 
LoM at days 2 (n=6), 6 (n=6), and 14 (n=6) post-exposure were compared with a 
two-sided Kruskal-Wallis with Dunn’s multiple comparisons test. d, SARS-CoV-2 
RNA in LoM human lung tissue 2 days post-exposure (SARS-CoV-2 RNA+, red; 
nuclei, blue; scale bars, 750 um [left image] and 250 um [right images], n=3).  
e, Virus nucleoprotein in LoM human lung tissue two-days post-exposure 
(positive cells, red; nuclei, blue; scale bars 200 um [left image] and 50 um [right 
images], n=6). f, Co-staining of LoM human lung tissue two days following 
SARS-CoV-2 exposure for virus nucleoprotein (red) and cytokeratin 19 
(epithelial cells, green, n=6), CD34 (endothelial cells, green, n= 4), or vimentin 
(mesenchymal cells, green, n=4). Nuclei, blue; scale bars 50 um. g, Co-staining 
of LoM human lung tissue two days following SARS-CoV-2 exposure for virus 
nucleoprotein (red) and acetylated alpha-tubulin IV (ciliated cells, green, n=6), 
CC10 (club cells, green, n=6), HT1-56 (alveolar type 1 cells, green, n=6), or 
Pro-SP-C (alveolar type 2 cells, green, n=3). Nuclei, blue; scale bars 50 um. In b 
and c, horizontal and vertical lines represent the median and interquartile 















Fig. 2 | Acute SARS-CoV-2 infection is highly cytopathic and causes 
extensive damage to human lung structures. a, H&E staining of a SARS-CoV-2 
infected LoM human lung tissue 2 days post-exposure (scale bar, 100 um, n=6). 
Arrows indicate protein globules. b-d, Immunohistochemical staining for virus 
nucleoprotein in LoM human lung tissue 2 days following SARS-CoV-2 exposure 
(positive cells, brown; b scale bars, 100 um; c and d scale bars, 50 um, n=6). 
 e-g, Martius Scarlet Blue staining of human lung tissue from e, naïve LoM (n=6) 
and f and g, SARS-CoV-2 infected LoM 2 days post-exposure (scale bars, 50 um; 
fibrin, red; collagen, blue, n=6). Arrows indicate the presence of fibrin (red) in f, 
alveoli or in g, thrombi of occluded vessels. h-l, Electron microscopy analysis of 
SARS-CoV-2 infected human lung tissue two days post-exposure (n=3). 
h, Uninfected AT2 cells in an alveolus-like structure. Scale bars, 2 um. 
i, SARS-CoV-2 infected AT2 cell. Higher magnification images of boxed areas 
show virus particles with dense nucleocapsids in RER. Scale bars, 2 um  
(left image), 1 um (middle image), and 200 nm (right image). j, Degenerative 
SARS-CoV-2 infected cell in the alveolar space. Arrows indicate virus filled 
vesicles. Scale bars, 1 um (left image), 200 nm (middle image), and 100 nm (right 
image). k and l, Blood vessels containing virions, fibrillar protein and cell 
debris. In k, scale bars, 5 um (left image) and 500 nm (right image). In l, scale 
bars, 2 um (right image) and 200 nm (left image). AS, alveolar space; AT1, 
alveolar type 1 cells; AT2, alveolar type 2 cells; BV, blood vessel; C, collagen;  
G, glycogen; LB, lamellar body; M, mitochondria; MO, monocyte;  
MV, microvilli; RER, rough endoplasmic reticulum. In c, i-l, black boxes indicate 















Fig. 3 | SARS-CoV-2 infection induces a strong and sustained host innate 
immune response in human lung tissue. a-d, RNA-sequencing analysis of 
human lung tissue collected from SARS-CoV-2 infected LoM. a, Log10 gene 
transcripts per million (TPM) in the human lungs of naïve LoM (n=2, x-axis) and 
SARS-CoV-2 infected (n=2, y-axis) LoM day 2 post-exposure. Genes of interest 
from Supplementary Tables 1 and 2 that appear increased (red) or decreased 
(blue) at least two-fold in SARS-CoV-2 infected LoM are shown. Genes having 
zero (0) mean TPM in either naïve or infected LoM are set at a minimum of log10 
(0.0001) TPM in order to visualize. b, Gene set enrichment analysis (GSEA) 
identified gene sets enriched in SARS-CoV-2 infected LoM human lungs. The 
pathway enrichment score is shown on the x-axis. The statistical significance of 
enrichment scores was determined using a two-sided empirical 
phenotype-based permutation test and adjusted for multiple testing using a 
False Discovery Rate (red, p<0.05). Heatmaps illustrating the expression of 
human c, interferon genes and d, cytokine/chemokine genes in human lung 
tissue collected analyzed from SARS-CoV-2 infected LoM days 2 (n=2), 6 (n=3), 
and 14 (n=3) post-exposure and naïve LoMs (n=4). Color scale indicates the 














Fig. 4 | Treatment and pre-exposure prophylaxis with EIDD-2801, a 
broad-spectrum anti-coronavirus drug, potently inhibit SARS-CoV-2 
infection in vivo. a, SARS-CoV-2 titers in the human lung tissue of LoM 
administered EIDD-2801 (n=8) or vehicle (n=8) 24 h post virus exposure.  
b, SARS-CoV-2 titers in the human lung tissue of LoM administered EIDD-2801 
(n=8) or vehicle (n=8) 48 h post virus exposure. c and d, SARS-CoV-2 titers in the 
human lung tissue of LoM administered EIDD-2801 (n=8 per experiment, 
yellow) or control vehicle (Ctrl, n=8 per experiment, blue) at 2 days 
post-exposure in two independent experiments shown c, separately and d, 
combined. e, Fold difference in SARS-CoV-2 titers in the human lung tissue of 
LoM relative to vehicle controls. f, H&E staining and g, immunohistochemical 
staining for virus nucleoprotein (positive cells, brown) of human lung tissue of 
LoM administered EIDD-2801 (n=8) or control vehicle (Ctrl, n=8) at 2 days 
post-exposure (scale bars, 100 um). a-d, Titers were compared with a two-tailed 
Mann-Whitney U test. Horizontal and vertical lines represent the median and 

















Animal studies were carried out according to protocols approved by 
the Institutional Use and Care Committee at UNC-Chapel Hill and in 
adherence to the NIH Guide for the Care and Use of Laboratory Ani-
mals. Mice were kept on a 12 h light/12 h dark cycle and housed in a 
temperature (20-23 °C) and humidity (30-70%) controlled vivarium 
maintained by the Division of Comparative Medicine at the University 
of North Carolina-Chapel Hill.
Experimental design
Human lung-only mice (LoM) were used as an in vivo model to evaluate 
infection of lung tissue with recombinant coronaviruses SARS-CoV, 
MERS-CoV, and SARS-CoV-2 as well as full length bat coronaviruses 
WIV1 and SHC01412,13,43,44. Viruses were directly injected into the human 
lung tissue of LoMs and lung tissue collected either 2, 6, or 14 days 
post-exposure for virus titer determination and/or analysis by histol-
ogy, electron microscopy, or RNA-seq.
Construction of humanized mice
LoMs were constructed with 1-2 human lung implants by surgically 
implanting human lung tissue (Advanced Bioscience Resources) sub-
cutaneously into the upper and lower back of male and female 12-21 
week old NOD.Cg-Prkdcscid ll2rgtm1Wjl/SzJ mice [NSG mice; The Jackson 
Laboratory] as previously described17. Engraftment of lung tissue was 
assessed by palpation and by 8 weeks post-surgery animals were ready 
for experimentation.
Production of coronavirus stocks and infection of humanized 
mice
Stocks of wild-type SARS-CoV, MERS-CoV (HCoV-EMC/2012), 
SHC014-CoV, and WIV1-CoV were derived from infectious virus clones 
and were prepared and titered on Vero E6 (SARS-CoV, SHC014-CoV, and 
WIV1-CoV) or Vero CCL81 cells (MERS-CoV) (American Type Culture 
Collection) as previously described6,12,13,17. Cell lines were authenticated 
by morphological identification and virus susceptibility profiles and 
tested for mycoplasma by the supplier. A clinical isolate of SARS-CoV-2 
(2019-nCoV/USA-WA1/2020) was obtained from the U.S. Centers for 
Disease Control and Prevention (GenBank accession no. MN985325.1) 
and passaged twice in Vero E6 cells to create a passage 5 working stock42. 
For the infection of mice with coronavirus, the fur over the human 
lung tissue of anesthetized mice was shaved and virus (1-3x105 PFU 
in 100 ul PBS) was injected directly into the lung tissue. To evaluate 
the in vivo inhibitory activity of EIDD-2801 pre-exposure prophylaxis, 
mice were administered 500 mg/kg EIDD-2801 or vehicle control 
(10% PEG and 2.5% Cremophor RH40 in water) via oral gavage start-
ing 12 h prior to SARS-CoV-2 exposure and every 12 h thereafter. The 
therapeutic efficacy of EIDD-2801 was assessed by administering mice 
500 mg/kg EIDD-2801 or vehicle control (10% PEG and 2.5% Cremophor 
RH40 in water) via oral gavage starting 24 h or 48 h post exposure and 
every 12 h thereafter. At necropsy, human lung tissues were collected, 
weighed (mean weight: 0.55 grams ± 0.05 s.e.m, n=32), homogenized, 
and stored at -80 °C until tittering on Vero E6 cells. Titers below the 
limit of the assay (50 PFU/mL) were assigned a value of 25 PFU/gram. 
No correlation was observed between SARS-CoV-2 titers (PFU/g) at 
2 days post-exposure and the timing post-surgery (p=0.4474, two-tailed 
Spearman’s rank correlation).
H&E staining of human lung tissue
Human lung tissues collected from LoM were fixed in 10% formalin, 
paraffin embedded, and cut into 5 µm sections which were mounted 
onto Superfrost Plus slides (Fisher Scientific). Tissue sections were 
incubated at 60 °C for 1 h, deparaffinized with xylene (2 × 3 min) 
and graded ethanol (100% 2 × 3 min, 95% 1 × 3 min, 80% 1x 3min, 
70% 1 × 3 min), and stained with hematoxylin followed by eosin. Tissue 
sections were then mounted and imaged on a Nikon Eclipse Ci micro-
scope using Nikon Elements BR software (version 4.30.01) with a Nikon 
Digital Sight DS-Fi2 camera. Brightness, contrast and white balance 
were adjusted on whole images in Adobe Photoshop (CS6).
Immunohistochemical analysis of coronavirus infection
Immunohistochemistry was performed as previously described17. 
Briefly, fixed (10% formalin) human lung tissues collected from 
coronavirus-infected LoM were paraffin embedded and sectioned 
(5 um). Tissue sections mounted on Superfrost Plus slides (Fisher Sci-
entific) were deparaffinized as described above. Following antigen 
retrieval using Diva Decloaker (BioCare Medical), non-specific binding 
was blocked using Background Sniper (BioCare Medical). Tissue sec-
tions were then incubated with primary antibodies against SARS-CoV 
nucleocapsid (1:500 or 1:1,000), MERS-CoV nucleocapsid (1:2,000), 
or TMPRSS2 (1:100) overnight at 4 °C. Tissue sections incubated with 
rabbit IgG were used as isotype controls. Tissue sections were then 
washed in TBST and the endogenous peroxidase activity blocked with 
hydrogen peroxide. Tissue sections were developed using the MACH-3 
polymer system (BioCare Medical) and 3,3′-diaminobenzidine (DAB) 
(Vector Laboratories), counterstained with hematoxylin, and mounted. 
Tissue sections were imaged on a Nikon Eclipse Ci microscope using 
Nikon Elements BR software (version 4.30.01) with a Nikon Digital Sight 
DS-Fi2 camera. Adobe Photoshop (CS6) was used to adjust brightness, 
contrast and white balance on whole images.
Immunofluorescence analysis of SARS-CoV2 infection
Human lung tissues collected from mice were fixed in 10% formalin and 
paraffin embedded. Immunofluoresence staining of 5 um tissue sec-
tions was performed as previously described17. Briefly, following depar-
affinization and antigen retrieval (Diva Decloaker), tissue sections were 
incubated with a 10% normal donkey serum solution with 0.1% Triton 
X-100 in 1x PBS to block non-specific binding. Tissue sections were 
then incubated overnight with primary antibodies at 4 °C followed 
by incubation with fluorescent conjugated secondary antibodies. 
Primary antibodies were directed against SARS nucleoprotein (1:500
or 1:1,000), ACE2 (1:200), human cytokeratin 19 (1:250), CD34 (1:100), 
vimentin (1:100), acetylated alpha-tubulin IV, CC10 (1:500), HT1-56 
(1:150), and pro-SP-C (1:500). Secondary antibodies were: Donkey 
anti-Mouse IgG heavy and light chains-AlexaFluor 488 (1:1,000), Don-
key anti-Rabbit IgG heavy and light chains-AlexaFluor 488(1:1,000), 
Donkey anti-Goat IgG heavy and light chains-AlexaFluor 594 (1:1,000), 
Donkey anti-Mouse IgG heavy and light chains-AlexaFluor Plus 594 
(1:1,000),
Donkey anti-Rabbit IgG heavy and light chains-AlexaFluor Plus 594 
(1:1,000), Donkey anti-Mouse IgG heavy and light chains-AlexaFluor 
647 (1:1,000). Background autofluorescence was then quenched using 
a 0.1% Sudan Black B solution in 80% ethanol prior to staining with DAPI. 
Slides were mounted and then imaged using an Olympus BX61 upright 
wide-field microscope using Volocity software (version 6.3) with a 
Hamamatsu ORCA RC camera. Appropriate negative controls without 
primary antibodies were also imaged using the same exposure time as 
matching stained sections. Whole image contrast, brightness, and pseu-
docoloring were adjusted using ImageJ/Fiji (Version 2.0.0-rc-69/1.51w) 
and Adobe Photoshop (version CS6).
RNA in situ hybridization (RNA-ISH) analysis of SARS-CoV2 
infection
RNA-ISH was performed on 10% formalin fixed, paraffin-embedded, 
5 µm sections of human lung tissues using the RNAscope 2.5 HD Rea-
gent Kit according to the manufacturer’s instructions (Advanced Cell 
Diagnostics). Briefly, tissue sections were mounted on Superfrost Plus 
microscope slides (Fisher Scientific), heated at 60 °C for 1 h, depar-














and air-dried. Tissue sections were then incubated with hydrogen 
peroxide to block endogenous peroxidases for 10 min at RT, followed 
by epitope retrieval (Advanced Cell Diagnostics) for 30 min in a 95 °C 
water bath. Subsequently, tissue sections were immediately washed 
in double distilled water then dehydrated in 100% ethanol for 2 min 
before air-drying. Tissue sections were then incubated with Protease 
Plus (Advanced Cell Diagnostics) for 30 min at 40 °C in a HybEZ hybridi-
zation oven (Advanced Cell Diagnostics). Sections were rinsed 3 times 
in double distilled water and then incubated with pre-warmed target 
probe designed to hybridize with the spike protein of SARS-CoV-2 (Cat. 
Number 848561, Advanced Cell Diagnostics) for 2 h at 40 °C. Tissue 
sections were then washed and the signal amplified according to the 
manufacturer’s instructions and developed using alkaline phosphatase 
and Fast Red substrate. Tissue sections were counterstained with DAPI, 
mounted with Prolong® Gold (Invitrogen), and imaged on an EVOS 
M5000 microscope (Invitrogen).
Electron microscopy analysis of SARS-CoV2 infection
Small pieces of human lung tissue collected from SARS-CoV-2 infected 
LoM at two days post-infection were fixed in 4% paraformaldehyde/2.5% 
glutaraldehyde in 0.15 M sodium phosphate buffer, pH 7.4, for 2 h at 
RT. The tissues were subsequently transferred to 10% formalin for 7 
days. Specimens were washed in 0.1 M sodium cacodylate, pH 7.4, then 
post-fixed with 1% cacodylate-buffered osmium tetroxide for 1 h. After 
washing in 0.05 M sodium cacodylate buffer, pH 7.0, the samples were 
treated with 1% tannic acid in 0.05 M sodium cacodylate buffer for 30 
min to enhance tissue contrast and preserve structure45. Tissue pieces 
were washed in deionized water, dehydrated in ethanol, and placed 
through two exchanges of propylene oxide before infiltration and 
embedment in PolyBed 812 epoxy resin (Polysciences). Semi-thin (1 µm) 
sections of tissue blocks were cut and stained with 1% toluidine blue 
in 1% sodium borate for examination by light microscopy. Ultra-thin 
(70 nm) sections were cut of selected regions of interest, mounted on 
200 mesh copper grids and stained with 4% aqueous uranyl acetate 
and Reynolds’ lead citrate. Grids were observed on a JEOL JEM 1230 
transmission electron microscope operating at 80kV ( JEOL USA, Inc.) 
and images were acquired with a Gatan Orius SC1000 CCD Digital 
Camera and Gatan Microscopy Suite software (version 3.0, Gatan, 
Inc.). Virus particle sizes were measured in Fiji/Image J (version 
2.0.0-rc-69/1.52p).
Processing of human lung tissues for RNA-sequencing analysis
Human lung tissues were collected in RNAlater and kept at 4 °C for 24 
h prior to storage at -80 °C until further processing. To isolate RNA, 
samples stored in RNAlater were thawed and the tissue transferred to 
a new tube containing 1 mm glass beads and 1 mL Trizol. Tissues were 
subsequently homogenized using a MagNA Lyser (Roche) for 30 sec 
at 6,000 rpm. In between rounds of homogenization, tissues were 
incubated on ice for 1 min. Following tissue homogenization, Trizol 
homogenate was transferred to a new tube and stored at -80 °C.
RNA-sequencing analysis
RNA was extracted from lung samples using a Trizol Plus RNA extrac-
tion kit (Thermo Fisher), quantified using a Qubit RNA assay kit and 
checked for quality using a Bioanalyzer RNA600 Nano kit (Agilent). 
RNA integrity scores were typically 7.0 and greater. 1ug of RNA was 
used to construct libraries for sequencing using a NEBNext Ultra II 
library prep kit with polyA RNA selection. Barcoded libraries were 
sequenced on a Novaseq 6,000 2x100 bp following manufacturer’s 
instructions (Illumina). Sequence quality was assessed using FASTQC 
(version 0.11.9). No issues were detected with the data and quality was 
typical for RNA extracted from fresh frozen material. A small amount of 
index hopping was detected (0.09%) due to the single indices used in the 
library preparation. Raw reads were mapped to the human, mouse, and 
SARS-CoV-2 reference genomes simultaneously (GRCh38.p13, GRCm38.
p6 M25, NC_045512, respectively) using the BBsplit function in BBmap 
(version 38.86). This step minimized cross mapping of reads among 
genomes. There was a non-significant, negative relationship between 
the amount of viral and human RNA reads (R2=0.136). We then mapped 
and quantified on a transcript and gene model basis using STAR (ver-
sion 2.7.5a) and Salmon (version 1.2.1)46,47. Reads mapping to multiple 
locations were dropped from analysis. On average, in the lung tissue 
samples from LoM mice, 80% of the reads mapped to human (standard 
deviation: +/- 6%), 19% mapped to mouse (standard deviation: +/- 6%) 
and 1% mapped to the SARS-CoV-2 genome (standard deviation: +/- 
1%). The percent of virus ranged from 0.05% to 3.4% among infected 
mice, with day 2 mice having the most, which is consistent with the 
infection titers observed. Samples from naïve mice were 95% or more 
human data.
Statistics and reproducibility
No statistical methods were used to predetermine sample size. No 
randomization was used to determine allocation of samples/animals 
to experimental groups and downstream analysis. The investigators 
were not blinded to group allocation for data collection and analysis. In 
Fig. 1b, titers for SARS-CoV and MERS-CoV represent two independent 
experiments and titers for SARS-CoV-2, WIV1-CoV, and SHC014-CoV 
represent one experiment. Virus titers between SARS-CoV-2 infected 
LoMs analyzed 2 post-exposure and days 6 and 14 post-exposure 
(Fig. 1c) were compared with a two-sided Kruskal-Wallis with Dunn’s 
multiple comparisons test and data represents one experiment. Pieces 
of human lung implants obtained from LoM in Fig. 1c were used for the 
RNAscope and immunofluorescence analysis shown in Fig. 1d–g, the 
histological and EM analyses in Fig. 2, and the RNA-seq gene expres-
sion analyses in Fig. 3, Extended Data Fig. 3, Extended Data Tables 3-5, 
and Supplementary Tables 1 and 2. The number of independent LoM 
human lung tissue samples analyzed for each parameter is indicated 
in the figure and table legends. RNA-sequencing data was normalized 
and interrogated for changes in gene expression using DESeq2 package 
(version 3.1.1) in R (version 3.6.3)48 and statistical tests were two-sided. 
We focused the analysis on the naïve controls versus LoM for days 2, 6, 
and 14 post-infection. Wald’s tests were performed contrasting each day 
versus naïve controls. Because mice were sacrificed at each time point, 
we treated each day independently and not as a time series. P-values 
were adjusted for multiple testing using a False Discovery Rate using 
the Benjamini & Hochberg method49. Data was analyzed both jointly 
and within each treatment compared to naïve controls. Differential 
expression of outliers was assessed and found insignificant in overall 
effect. Graphs and summary tables were built in R using ggplot; gene set 
enrichment was performed using GSEA and GO analysis (tidyverse 1.3.0; 
PCATools 1.2.0; Sqldf 0.4-11; na.tools 0.3.1; ggbiplot 0.55; ggplot2 3.3.1; 
dplyr 0.8.4). The statistical significance of GSEA calculated enrichment 
scores was determined using an empirical phenotype-based permuta-
tion test50 and P-values adjusted for multiple testing using a False Dis-
covery Rate using the Benjamini & Hochberg method49. Specific gene 
sets of interest were then interrogated for patterns of expression across 
treatment and time using unsupervised clustering of normalized gene 
expression counts. Gene Ontology (GO) analysis and visualization were 
performed with Gorilla (no version)51. Data was uploaded to the NCBI 
GEO archive (accession: GSE155286). In Fig. 4, virus titers in vehicle 
control and EIDD-2801 dosed LoM were compared with a two-sided 
Mann-Whitney U test (GraphPad Prism, version 8.0 or R, version 3.5.3). 
The effect of EIDD-2801 treatment on virus titers (Fig. 4a,b) represents 
one experiment and the effect of EIDD-2801 prophylaxis (Fig. 4c–e) 
represents two independent experiments. All independent attempts 
of repetition were completed with similar results.
Reporting summary
Further information on research design is available in the Nature 















Gene-expression data are available at the Gene Expression Omnibus 
(GEO) repository (accession: GSE155286). Source data is provided for 
Fig. 1b, c and Fig. 4a–d. All other data is available from corresponding 
authors on reasonable request. Publicly available data sets used in this 
study: 1) sequence of the SARS-CoV-2 strain 2019-nCoV/USA-WA1/2020 
(GenBank accession: MN985325.1) and 2) human lung tissue gene 
expression data profiled by the GTEx project (https://gtexportal.org/
home/; data retrieved 10/20/2020 and 11/3/2020). Source data are 
provided with this paper.
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Extended Data Fig. 1 | Human epithelial cells in the human lung tissue of 
LoMs express ACE2. a, H&E staining of the human lung tissue of a naïve LoM 
(scale bars 500 um [left image] and 100 um [right images], n=6). Boxes indicate 
regions shown in higher magnification images (right images) of cartilaginous 
airways (top) and non-cartilaginous airways and alveoli (bottom). 
Immunofluorescence staining for b, human cytokeratin 19 (epithelial cells, 
green; nuclei, blue; scale bar 50 um), CD34 (endothelial cells, green; nuclei, 
blue; scale bar 50 um), and vimentin (mesenchymal cells, green; nuclei, blue; 
scale bar 50 um). n=8 tissues analyzed. c, human ACE2 in the human lung  
tissue of a naïve LoM (positive cells, red; nuclei, blue; scale bar 50 um, n=9).  
d, Co-staining for human ACE2 (positive cells, red) and cytokeratin 19 (positive 
cells, green) in naïve LoM human lung tissue (nuclei, blue; scale bar 50 um, n=9). 
e, Immunohistochemical staining for TMPRSS2 in naïve LoM human lung tissue 
(positive cells, brown; scale bar, 100 um; n=6). n=number of biologically 















Extended Data Fig. 2 | Viral nucleoprotein in the human lung tissues  
of LoM infected with recently emerged human coronaviruses and bat 
coronaviruses. Immunohistochemical staining for virus nucleoprotein in 
human lung tissue collected from a, LoM two days post exposure to recently 
emerged human coronaviruses SARS-CoV (n=4), MERS-CoV (n=5), or 
SARS-CoV-2 (n=6), b, LoM two days post exposure to bat coronaviruses 
WIV1-CoV or SHC014-CoV (n=10), or c, naïve LoM (n=6). Positive cells, brown. 














Extended Data Fig. 3 | SARS-CoV-2 infection of human epithelial cell types 
in the human lung tissue of LoM. Single color and merged images of those 
shown in Fig. 1f and g depicting co-staining of LoM human lung tissue two days 
following SARS-CoV-2 exposure for virus nucleoprotein (red) and a, and 
cytokeratin 19 (epithelial cells, green, n=6), CD34 (endothelial cells, green,  
n= 4), or vimentin (mesenchymal cells, green, n=4) or b, acetylated 
alpha-tubulin IV (ciliated cells, green, n=6), CC10 (club cells, green, n=6),  
HT1-56 (alveolar type 1 cells, green, n=6), or Pro-SP-C (alveolar type 2 cells, 
green, n=3). Nuclei, blue; scale bars 50 um. n=number of biologically 















Extended Data Fig. 4 | Experimental design for the evaluation of EIDD-2801 
as treatment or pre-exposure prophylaxis for SARS-CoV-2 infection.  
a, Treatment experimental design. LoM were orally administered EIDD-2801 or 
vehicle at 24 h or 48 h post SARS-CoV-2 exposure and every 12 h thereafter. 
Virus titers were measured 2 days post-treatment initiation. b, Pre-exposure 
prophylaxis experimental design. LoM were orally administered EIDD-2801 or 
vehicle control 12 h prior to SARS-CoV-2 exposure and every 12 h thereafter. 














Extended Data Table 1 | Description of LoM used for the 














Extended Data Table 2 | Description of LoM used for the 















Extended Data Table 3 | Abundance of viral transcripts 
detected in SARS-CoV-2 infected LoM
Shown is the %viral transcripts of total transcripts sequenced from SARS-CoV-2 infected (n=8) 
and naïve (n=4) LoM utilized for RNA-sequencing analysis. Not applicable: N/A. Using a linear 
model, there was no effect of human donor on viral transcript abundance (lm() in R: estimate 














Extended Data Table 4 | Abundance of human ACE2 and 
TMPRSS2 transcripts detected in SARS-CoV-2 infected LoM
Shown are the abundance of human GAPDH, ACE2, and TMPRSS2 transcripts sequenced in 
the human lung tissue collected from naïve (n=4) and SARS-CoV-2 infected (n=8) LoM. Median 
ACE2 and TMPRSS2 expression in human lung tissue of naïve mice was 0.75 TPM and 35.6 TPM 
respectively, which is comparable to the median expression of ACE2 (1.01 TPM) and TMPRSS2 
(43.2 TPM) observed in human lung tissue profiled by the GTEx project (https://gtexportal.
org/home/; data retrieved 10/20/2020 and 11/3/2020). No effect of human donor on ACE2 
expression (F = 2.06259641; p=0.1756 via two-sided ANOVA) was observed. Approximately the 
same amount of variation was observed within a human donor (mean variance within donors = 















Extended Data Table 5 | Human interferon and cytokine genes upregulated during SARS-CoV-2 infection
Transcripts per million (TPM). Log2 fold change (Log2FC) in TPM detected in LoM human lung tissues at 2 (n=2), 6 (n=3), and 14 (n=3) days post-SARS-CoV-2 exposure compared to naïve controls 
(n=4). P-values were calculated in DESeq2 using a two-sided Wald’s test and adjusted for multiple testing using a False Discovery Rate. Not applicable (N/A): DESeq2 could not calculate a 














Extended Data Table 6 | Description of LoM used to evaluate 
the efficacy of EIDD-2801 for SARS-CoV-2 pre-exposure 
prophylaxis and treatment
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